- Home
- / Eton Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Eton Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$8.5
2024-10-29
Market Capitalization
$220.6 M
2024-10-29
Revenue
$80 M
FY, 2025
CreditSafe Score
?
Score changed on Jul 22, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 959.0K | 39.0K | 21.8M | 21.3M | 31.6M | 39.0M | 80.0M | ||
| Cost of goods sold | 453.0K | 286.0K | 6.9M | 10.6M | 15.6M | 37.2M | |||
| Gross profit | 506.0K | (247.0K) | 19.2M | 14.3M | 21.1M | 23.4M | 42.7M | ||
| Gross profit margin, % | 52.8% | -633.3% | 88.0% | 67.4% | 60.0% | 53.5% | |||
| General and administrative expense | 3.2M | 4.7M | 7.6M | 12.8M | 14.5M | 18.6M | 18.9M | 22.8M | 35.8M |
| Operating expense total | 7.2M | 10.3M | 19.1M | 26.9M | 20.7M | 22.6M | 22.3M | 26.0M | 43.6M |
| Depreciation and amortization | 41.0K | ||||||||
| EBIT | (18.6M) | (27.1M) | (1.5M) | (8.3M) | (1.2M) | (2.6M) | (844.0K) | ||
| EBIT margin, % | -1939.6% | -69515.4% | -6.8% | -38.9% | -6.7% | -1.1% | |||
| Interest income | 281.0K | ||||||||
| Interest expense | 884.0K | 1.0M | 955.0K | 1.1M | 2.0M | ||||
| Pre tax profit | (18.3M) | (28.0M) | (2.0M) | (9.0M) | (689.0K) | (3.8M) | (4.6M) | ||
| Income tax expense | 247.0K | 15.0K | 43.0K | ||||||
| Net Income | (7.2M) | (12.7M) | (18.3M) | (28.0M) | (2.0M) | (9.0M) | (936.0K) | (3.8M) | (4.6M) |